Bruno Oliveira de Figueiredo Brito

Bruno Oliveira de Figueiredo Brito

Auto-generated profile, based on publicly available information

Bruno Oliveira de Figueiredo Brito

Affiliations Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, Serviço de Cardiologia e Cirurgia Cardiovascular, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
MNMaria Carmo Pereira Nunes
Maria Carmo Pereira Nunes
LBLewis F. Buss
Lewis F. Buss
JSJose Luiz P. Silva
Jose Luiz P. Silva
LMLarissa Natany Almeida Martins
Larissa Natany Almeida Martins
COClaudia Di Lorenzo Oliveira
Claudia Di Lorenzo Oliveira
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
Background: There are few contemporary cohorts of Trypanosoma cruzi –seropositive individuals, and the basic clinical epidemiology of Chagas disease is poorly understood. Herein, we report the incidence of cardiomyopathy and death associated with T. cruzi seropositivity. Methods: Participants were selected in blood banks at 2 Brazilian centers. Cases were defined as T. cruzi –seropositive blood donors. T. cruzi –seronegative controls were matched for age, sex, and period of donation. Patients with established Chagas cardiomyopathy were recruited from a tertiary outpatient service. Participants underwent medical examination, blood collection, ECG, and echocardiogram at enrollment (2008–2010) and at follow-up (2018–2019). The primary outcomes were all-cause mortality and development of cardiomyopathy, defined as the presence of a left ventricular ejection fraction <50% or QRS complex duration ≥120 ms, or both. To handle loss to follow-up, a sensitivity analysis was performed using inverse probability weights for selection. Results: We enrolled 499 T. cruzi –seropositive donors (age 48±10 years, 52% male), 488 T. cruzi –seronegative donors (age 49±10 years, 49% male), and 101 patients with established Chagas cardiomyopathy (age 48±8 years, 59% male). The mortality in patients with established cardiomyopathy was 80.9 deaths/1000 person-years (py) (54/101, 53%) and 15.1 deaths/1000 py (17/114, 15%) in T. cruzi –seropositive donors with cardiomyopathy at baseline. Among T. cruzi –seropositive donors without cardiomyopathy at baseline, mortality was 3.7 events/1000 py (15/385, 4%), which was no different from T. cruzi –seronegative donors with 3.6 deaths/1000 py (17/488, 3%). The incidence of cardiomyopathy in T. cruzi –seropositive donors was 13.8 (95% CI, 9.5–19.6) events/1000 py (32/262, 12%) compared with 4.6 (95% CI, 2.3–8.3) events/1000 py (11/277, 4%) in seronegative controls, with an absolute incidence difference associated with T. cruzi seropositivity of 9.2 (95% CI, 3.6–15.0) events/1000 py. T. cruzi antibody level at baseline was associated with development of cardiomyopathy (adjusted odds ratio, 1.4 [95% CI, 1.1–1.8]). Conclusions: We present a comprehensive description of the natural history of T. cruzi seropositivity in a contemporary patient population. The results highlight the central importance of anti– T. cruzi antibody titer as a marker of Chagas disease activity and risk of progression.

6 December 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
BBBruno Oliveira de Figueiredo Brito
Bruno Oliveira de Figueiredo Brito
ZAZachi I. Attia
Zachi I. Attia
LMLarissa Natany A. Martins
Larissa Natany A. Martins
PPPablo Perel
Pablo Perel
MNMaria Carmo P. Nunes
Maria Carmo P. Nunes
FLFrancisco Lope-Jimenez
Francisco Lope-Jimenez
Left ventricular systolic dysfunction (LVSD) in Chagas disease (ChD) is relatively common and its treatment using low-cost drugs can improve symptoms and reduce mortality. Recently, an artificial intelligence (AI)-enabled ECG algorithm showed excellent accuracy to detect LVSD in a general population, but its accuracy in ChD has not been tested. To analyze the ability of AI to recognize LVSD in patients with ChD, defined as a left ventricular ejection fraction determined by the Echocardiogram ≤ 40%. This is a cross-sectional study of ECG obtained from a large cohort of patients with ChD named São Paulo-Minas Gerais Tropical Medicine Research Center (SaMi-Trop) Study. The digital ECGs of the participants were submitted to the analysis of the trained machine to detect LVSD. The diagnostic performance of the AI-enabled ECG to detect LVSD was tested using an echocardiogram as the gold standard to detect LVSD, defined as an ejection fraction <40%. The model was enriched with NT-proBNP plasma levels, male sex, and QRS ≥ 120ms. Among the 1,304 participants of this study, 67% were women, median age of 60; there were 93 (7.1%) individuals with LVSD. Most patients had major ECG abnormalities (59.5%). The AI algorithm identified LVSD among ChD patients with an odds ratio of 63.3 (95% CI 32.3–128.9), a sensitivity of 73%, a specificity of 83%, an overall accuracy of 83%, and a negative predictive value of 97%; the AUC was 0.839. The model adjusted for the male sex and QRS ≥ 120ms improved the AUC to 0.859. The model adjusted for the male sex and elevated NT-proBNP had a higher accuracy of 0.89 and an AUC of 0.874. The AI analysis of the ECG of Chagas disease patients can be transformed into a powerful tool for the recognition of LVSD. Chagas disease (ChD) is caused by the protozoan parasite Trypanosoma cruzi and continues to be a health problem despite the control of its transmission. ChD is a heterogeneous condition with a wide variation in its clinical course and prognosis. The majority (60%–70%) of infected individuals remain asymptomatic throughout life. Although some develop only conduction defects and mild segmental wall motion abnormalities, others develop severe symptoms of heart failure (HF), thromboembolic phenomena, and life threatening ventricular arrhythmias. HF is one of major causes of the death of patients with ChD. There is some evidence on effective drugs against the parasite in the chronic form of the disease capable of preventing long-term adverse outcomes, but it is still limited. However low-cost medications are able to reduce mortality and improve the quality of life of patients with HF. Because of the lack of tertiary care facilities outside urban centers, an automatic diagnostic tool based on the ECG, which is a relatively simple exam without requiring human interpretation, would improve the capacity to recognize HF. Recently, digital signals of the electrocardiogram were recognized by Artificial Intelligence (AI) and associated with an excellent accuracy for HF in the general population. Our results demonstrate that AI-ECG could ensure a rapid recognition of HF in patients who require a referral to a cardiologist and the use of disease-modifying drugs. AI can be used as a powerful public heath tool, it can transform the lives of 6 million patients with ChD worldwide, and it may well have a formidable impact on patient management and prognosis.

1 November 2018 in Journal of Electrocardiology
Verified
Journal Article
Closed access
BBBruno Oliveira de Figueiredo Brito
Bruno Oliveira de Figueiredo Brito
MPMarcelo Martins Pinto-Filho
Marcelo Martins Pinto-Filho
CCClareci Silva Cardoso
Clareci Silva Cardoso
COClaudia Di Lorenzo Oliveira
Claudia Di Lorenzo Oliveira
AFAriela Mota Ferreira
Ariela Mota Ferreira
ARAntonio Luiz Ribeiro
Antonio Luiz Ribeiro

7 June 2023 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
BBBruno Oliveira Figueiredo Brito
Bruno Oliveira Figueiredo Brito
ELEmilly Malveira Lima
Emilly Malveira Lima
ESElsayed Z. Soliman
Elsayed Z. Soliman
ESEduardo Fernandes Silva
Eduardo Fernandes Silva
MLMaria Fernanda Lima-Costa
Maria Fernanda Lima-Costa
ARAntonio Luiz Ribeiro
Antonio Luiz Ribeiro
Background: The natural history of Chagas disease (ChD) in older ages is largely unknown, and it is a matter of controversy if the disease continues to progress in the elderly. Objective: To investigate the evolution of electrocardiographic abnormalities in T. cruzi chronically infected community-dwelling elderly compared to non-infected (NChD) subjects and how it affects this population’s survival in a follow-up of 14 years. Methods and results: A 12-lead ECG of each individual of the Bambui Cohort Study of Aging was obtained in 1997, 2002, and 2008, and the abnormalities were classified using the Minnesota Code. The influence of ChD on the ECG evolution was assessed by semi-competing risks considering a new ECG abnormality as the primary event and death as the terminal event. A Cox regression model to evaluate the population survival was conducted at a landmark point of 5.5 years. The individuals of both groups were compared according to the following categories: Normal, Maintained, New, and More by the development of ECG major abnormalities between 1997 and 2002. Among the participants, the ChD group had 557 individuals (median age: 68 years) and NChD group had 905 individuals (median age: 67 years). ChD was associated with a higher risk of development of a new ECG abnormality [HR: 2.89 (95% CI 2.28–3.67)]. The development of a new major ECG abnormality increases the risk of death ChD patients compared to those that maintain a normal ECG [HR: 1.93 (95% CI 1.02–3.65)]. Conclusion: ChD is still associated with a higher risk of progression to cardiomyopathy in the elderly. The occurrence of a new major ECG abnormality in ChD patients predicts a higher risk of death.